pCODR Final Recommendation Issued for ibrutinib (Imbruvica) for Mantle Cell Lymphoma (MCL)

Health Canada Approves Venetoclax for CLL Patients With 17P deletion or if No Other Treatment Options are Available

Lymphoma Canada 2016 Research Fellowship Award

Health Canada Approves ibrutinib for Waldenström’s Macroglobulinemia